Ana Beatriz Pérez

Ana Beatriz Pérez

Auto-generated profile, based on publicly available information

Ana Beatriz Pérez

Cellular Immunology Laboratory, Virology Department, Tropical Medicine Institute “Pedro Kourí”, Autopista Novia del Medio Día Km 6 ½, La Habana 11400, Cuba

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in Human Immunology
Verified
Journal Article
Closed access
APAna B. Perez
Ana B. Perez
BSBeatriz Sierra
Beatriz Sierra
GGGissel Garcia
Gissel Garcia
EAEglis Aguirre
Eglis Aguirre
NBNina Babel
Nina Babel
MGMaria G. Guzman
Maria G. Guzman

26 April 2004 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
APAna B. Pérez
Ana B. Pérez
GGGissel García
Gissel García
BSBeatriz Sierra
Beatriz Sierra
MAMayling Alvarez
Mayling Alvarez
SVSusana Vázquez
Susana Vázquez
MGMaría G. Guzmán
María G. Guzmán

10 September 2020 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
FOFaith Osier
Faith Osier
JTJenny P. Y. Ting
Jenny P. Y. Ting
JFJohn Fraser
John Fraser
BLBart N. Lambrecht
Bart N. Lambrecht
MRMarta Romano
Marta Romano
MSMelinda Suchard
Melinda Suchard

13 December 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
Gissel García MenéndezGissel García Menéndez
Gissel García Menéndez
JSJosanne Soto
Josanne Soto
AMAntonio Díaz Machado
Antonio Díaz Machado
JBJesús Barreto
Jesús Barreto
CSCarmen Soto
Carmen Soto
Raul De Jesús CanoRaul De Jesús Cano
Raul De Jesús Cano
(1) Background: Heyndrickxia coagulans, a lactic acid-producing bacterium, displays characteristics of both Lactobacillus and Bacillus genera. Clinical evidence suggests its potential health benefits. This study evaluated the safety of H. coagulans AO1167B as a candidate probiotic supplement. (2) Methods: Strain identification was confirmed through morphological, cultural, and genomic analyses, including 16S RNA and whole genome sequencing to assess antimicrobial resistance and virulence factors. Phenotypic tests, such as disk diffusion for antimicrobial resistance, and safety assays for cytotoxicity and hemolytic activity, were conducted. In a phase I, double-blind, placebo-controlled clinical trial, healthy adults were randomized into H. coagulans AO1167B and placebo groups for 60 days. Daily capsule consumption was monitored through clinical and hematological evaluations, adverse event tracking, and health surveys. (3) Results: The genome of H. coagulans AO1167B revealed no concerning features. Disk diffusion tests showed no antimicrobial resistance. The strain exhibited no cytotoxic or hemolytic activity, indicating in vitro safety. No significant differences in clinical or hematological parameters were observed between groups. The most common adverse event, gas, diminished over time. (4) Conclusions: H. coagulans AO1167B demonstrates a suitable safety profile, genetic stability, and probiotic potential for gastrointestinal health, justifying further clinical research.

12 November 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
Gissel García MenéndezGissel García Menéndez
Gissel García Menéndez
JSJosanne Soto
Josanne Soto
AMAntonio Díaz Machado
Antonio Díaz Machado
JBJesús Barreto
Jesús Barreto
CSCarmen Soto
Carmen Soto
Raul De Jesús CanoRaul De Jesús Cano
Raul De Jesús Cano
(1) Background: Alkalihalobacillus clausii AO1125 is a Gram-positive, motile, spore-forming bacterium with potential as a probiotic due to its broad-spectrum antimicrobial activity, inhibiting pathogens like Listeria monocytogenes, Staphylococcus aureus, and Clostridium difficile, as well as anti-rotavirus activity. Its resilience in gastrointestinal conditions suggests benefits for gut health. This study evaluates the safety and probiotic potential of A. clausii AO1125. (2) Methods: Genome annotation identified genes linked to probiotic traits such as stress resistance, gut colonization, immune modulation, and antimicrobial production. The genome was screened for antibiotic resistance genes using CARD, bacteriocin clusters using BAGEL4, and virulence factors via VFDB. Cytotoxicity was assessed on Vero cells and erythrocytes, and a Phase I, double-blind, placebo-controlled clinical trial was conducted with 99 healthy volunteers (50 AO1125, 49 placebo). (3) Results: Genomic analysis confirmed minimal antibiotic resistance genes and the absence of virulence factors, supporting safety. A. clausii AO1125 showed no pathogenicity, cytotoxicity, or hemolytic activity and was well-tolerated in clinical settings, with mild, transient abdominal gas as the most common adverse event. (4) Conclusions: The safety profile and genetic basis for probiotic and antimicrobial properties support A. clausii AO1125 as a promising probiotic candidate for gastrointestinal health, warranting further clinical research.

4 August 2021 in Viruses
Verified
Journal Article
Open access
PDF file
BSBeatriz Sierra
Beatriz Sierra
AMAna Cristina Magalhaes
Ana Cristina Magalhaes
DSDaniel Soares
Daniel Soares
BCBruno Cavadas
Bruno Cavadas
APAna B. Perez
Ana B. Perez
MGMaria G Guzman
Maria G Guzman
Transcriptomics, proteomics and pathogen-host interactomics data are being explored for the in silico–informed selection of drugs, prior to their functional evaluation. The effectiveness of this kind of strategy has been put to the test in the current COVID-19 pandemic, and it has been paying off, leading to a few drugs being rapidly repurposed as treatment against SARS-CoV-2 infection. Several neglected tropical diseases, for which treatment remains unavailable, would benefit from informed in silico investigations of drugs, as performed in this work for Dengue fever disease. We analyzed transcriptomic data in the key tissues of liver, spleen and blood profiles and verified that despite transcriptomic differences due to tissue specialization, the common mechanisms of action, “Adrenergic receptor antagonist”, “ATPase inhibitor”, “NF-kB pathway inhibitor” and “Serotonin receptor antagonist”, were identified as druggable (e.g., oxprenolol, digoxin, auranofin and palonosetron, respectively) to oppose the effects of severe Dengue infection in these tissues. These are good candidates for future functional evaluation and clinical trials.